nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2017 | Antiphospholipid Syndrome (S Zuily, Section Editor)

Does APS Impact Women’s Fertility?

verfasst von: Cecilia Beatrice Chighizola, Maria Gabriella Raimondo, Pier Luigi Meroni

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review focuses on the relationship between anti-phospholipid antibodies (aPL) and female infertility by addressing three key questions: (i) how can aPL induce women’s infertility?; (ii) are aPL more prevalent among infertile than fertile women?; (iii) do aPL-positive women display reduced fertility?

Recent Findings

According to experimental data, aPL impair female fertility interfering with endometrial decidualization thus with implantation. Some aPL tests are more frequently detected among infertile women compared to controls; the association between aPL and assisted reproduction techniques outcome is not supported by most studies. Two reports suggest a decreased ovarian reserve among aPL-positive patients, while fertility is preserved in women with systemic lupus erythematosus, commonly associated with aPL positivity. Pregnancy rates drop after diagnosis and lupus women have fewer children than wished, due to many disease-related factors.

Summary

While awaiting definitive conclusions on the relationship between aPL and infertility, rheumatologists should properly counsel female patients to safeguard fertility.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.CrossRefPubMed

Chighizola CB, Gerosa M, Trespidi L, Di Giacomo A, Rossi F, Acaia B, et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev Clin Immunol. 2014;10(11):1505–17.CrossRefPubMed

Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9(5):A299–304.CrossRefPubMed

Deroux A, Dumestre-Perard C, Dunand-Faure C, Bouillet L, Hoffmann P, et al. 2016 Female infertility and serum autoantibodies: a systematic review. Clin Rev Allergy Immunol.

•• Chighizola CB, de Jesus GR, Branch WD. The hidden world of anti-phospholipid antibodies and female infertility: a literature appraisal. Autoimmun Rev. 2016;15(6):493–500. This critical revision of the literature presents the estimated positivity rates of anti-phospholipid antibodies among infertile women, the effects of anti-phospholipid positivity on the outcome of assisted reproduction techniques and the impact of treatment on the outcome of assisted reproduction techniques. CrossRefPubMed

Di Simone N, Di Nicuolo F, D’Ippolito S, Castellani R, Tersigni C, Caruso A, et al. Antiphospholipid antibodies affect human affect human endometrial angiogenesis. Biol Reprod. 2010;83(2):212–9.CrossRefPubMed

Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol. 1990;163(1 Pt 1):210–6.CrossRefPubMed

Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195(2):211–20.CrossRefPubMedPubMedCentral

Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11):1644–54.CrossRefPubMedPubMedCentral

10.

Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Med. 2004;10(11):1222–6.CrossRefPubMed

11.

Francis J, Rai R, Sebire NJ, El-Gaddal S, Fernandes MS, Jindal P, et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod. 2006;12(7):435–42.CrossRefPubMed

12.

• Chighizola CB, Pregnolato F, Raschi E, Grossi C, Gentilini D, Borghi MO, et al. Antiphospholipid antibodies and infertility: a gene expression study in decidual stromal cells. Isr Med Assoc J. 2016;18(3–4):146–9. This very recent gene expression study provides in vitro support to the potential pathogenicity of anti-phospholipid antibodies in mediating female fertility by impairing decidualization. PubMed

13.

Chaouat G. Inflammation, NK cells and implantation: friend and foe (the good, the bad and the ugly?): replacing placental viviparity in an evolutionary perspective. J Reprod Immunol. 2013;97(1):2–13.CrossRefPubMed

14.

Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril. 2008;90(5 Suppl):S172–3.

15.

Ostensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18(2):219–32.CrossRefPubMed

16.

Oktem O, Yagmur H, Bengsiu H, Urman B. Reproductive aspects of systemic lupus erythematosus. J Reprod Immunol. 2016;117:57–65.CrossRefPubMed

17.

• Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14(5):376–86. This review summarizes the current knowledge on how to manage pregnancy in women with rheumatic disease. CrossRefPubMed

18.

Skomsvoll JF, Ostensen M, Schei B. Reproduction in women reporting chronic musculoskeletal disorders. Scand J Rheumatol. 2000;29(2):103–7.CrossRefPubMed

19.

Yamakami LY, Serafini PC, de Araujo DB, Bonfá E, Leon EP, Baracat EC, Silva CA. Ovarian reserve in women with primary antiphospholipid syndrome. Lupus. 2014;23(9):862–7.CrossRefPubMed

20.

Vega M, Barad DH, Yu Y, Darmon SK, Weghofer A, Kushnir VA, Gleicher N. Anti-mullerian hormone levels decline with the presence of antiphospholipid antibodies. Am J Reprod Immunol. 2016;76(4):333–7.CrossRefPubMed

21.

Pasoto SG, Abrao MS, Viana VS, Bueno C, Leon EP, Bonfa E. Endometriosis and systemic lupus erythematosus: a comparative evaluation of clinical manifestations and serological autoimmune phenomena. Am J Reprod Immunol. 2005;53(2):85–93.CrossRefPubMed

22.

Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50(9):1551–8.CrossRef

23.

Fraga A, Mintz G, Orozco J, Orozco JH. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol. 1974;1:293–8.

24.

Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol. 1993;20(4):650–6.PubMed

25.

Hardy CJ, Palmer BP, Morton SJ, Muir KR, Powell RJ. Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford). 1999;38(6):559–63.CrossRef

26.

Ekblom-Kullberg S, Kautiainen H, Alha P, Helve T, Leirisalo-Repo M, Julkunen H, et al. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol. 2009;38(5):375–809.CrossRefPubMed

27.

Clowse MEB, Chakravarty E, Costenbader KH, Chambers C, Michaud K. The effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012;64(5):668–74.CrossRef

28.

Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193–7.CrossRefPubMed

29.

Ma W, Zhan Z, Liang X, Chen J, Huang X, Liao C. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Women's Health. 2013;22(12):1023–7.CrossRef

30.

Malheiro OB, Rezende CP, Rocha AL, Del Puerto HL, Ferreira GA, Reis FM. Regular menstrual cycles do not rule out ovarian damage in adult women with systemic lupus erythematosus. Gynecol Endocrinol. 2014;30(10):701–4.CrossRefPubMed

31.

Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785–92.CrossRefPubMed

32.

Gasparin AA, Souza L, Siebert M, Xavier RM, Chakr RM, Palominos PE, et al. Assessment of anti-Mullerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus. 2016;25(3):227–32.CrossRefPubMed

33.

Velarde-Ochoa Mdel C, Esquivel-Valerio JA, Vega-Morales D, Skinner-Taylor CM, Galarza-Delgado DÁ, Garza-Elizondo MA. Anti-Müllerian hormone in reproductive age women with systemic lupus erythematosus. Reumatol Clin. 2015;11(2):78–82.CrossRefPubMed

34.

Sundqvist J, Falconer H, Seddighzadeh M, Vodolazkaia A, Fassbender A, Kyama C, et al. Endometriosis and autoimmune disease: association of susceptibility to moderate/severe endometriosis with CCL21 and HLA-DRB1. Fertil Steril. 2011;95(1):437–40.CrossRefPubMed

35.

Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17(10):2715–24.CrossRefPubMed

36.

Nielsen NM, Jorgensen KT, Pedersen BV, Rostgaard K, Frisch M. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome. Hum Reprod. 2011;26(6):1555–9.CrossRefPubMed

37.

Matorras R, Ocerin I, Unamuno M, Nieto A, Peiro E, Burgos J, et al. Prevalence of endometriosis in women with systemic lupus erythematosus and Sjogren’s syndrome. Lupus. 2007;16(9):736–40.CrossRefPubMed

38.

Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441–7.CrossRefPubMedPubMedCentral

39.

Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063–75.CrossRefPubMed

40.

Mendonca LL, Khamashta MA, Nelson-Piercy C, Hunt BJ, Hughes GR. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford). 2000;39(8):880–2.CrossRef

41.

Sookvanichsilp N, Pulbutr P. Anti-implantation effects of indomethacin and celecoxib in rats. Contraception. 2002;65(5):373–8.CrossRefPubMed

42.

Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65(1):206–10.CrossRefPubMed

43.

Aune B, Høie KE, Oian P, Holst N, Osterud B. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state? Hum Reprod. 1991;6:925–7.CrossRefPubMed

44.

Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000;43:550–6.CrossRefPubMed

45.

Huong DL, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Lefebvre G, et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum. 2002;32:174–88.CrossRefPubMed

46.

Ragab A, Barakat R, Ragheb M, State O, Badawy A. Subfertility treatment in women with systemic lupus erythematosus. J Obstet Gynaecol. 2012;32:569–71.CrossRefPubMed

47.

Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803–10.CrossRefPubMed

48.

•• Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2016; doi:10.1136/annrheumdis-2016-209770. This paper provides the most recent recommendations from EULAR on women’s health and family planning, which might be useful in clinical practice. PubMed

Titel: Does APS Impact Women’s Fertility?
verfasst von: Cecilia Beatrice Chighizola
Maria Gabriella Raimondo
Pier Luigi Meroni
Publikationsdatum: 01.06.2017
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2017
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-017-0663-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Does APS Impact Women’s Fertility?